RBD-SpyCatcher-mi3 vaccine construct could be a promising candidate for broad protection against SARS-CoV-2 variants, advocating for further clinical testing.
ProSci has generated several antibody reagents for SARS-CoV-2 research. Two of these antibodies were used in research by Yunguang Sun and colleagues.
MBL International provides QuickSwitch™ Tetramers for the Quant Analysis of SARS-CoV-2 mRNA Vaccinations.
ProSci Incorporated has been selected as the 2022 Bioz Stars Award Winner in the COVID-19 Category.
To support research & studies into infectious diseases, ProSci has reagents for the study of many viral disease agents inc. Covid, HIV, & Influenza.
As viruses create more of themselves, they mutate – single-point changes in genetic code. SARS-CoV-2 virus mutated to be more transmissible.
The cytokine storm is a relatively new discovery & is actively being studied. ProSci offers cytokine & chemokine antibodies & recombinant proteins.
The SARS-CoV-2 genome is ~29 kb divided into 10 ORFs. Each of these ORFs (except seemingly ORF10) is translated in 29 different proteins.
Research continues in understanding mechanisms of SARS-CoV-2 immune evasion. ProSci offers antibodies & recombinant proteins for SARS-CoV-2 research.
ProSci has developed SARS-CoV-2 variant-specific reagents by focusing on unique point mutations in the spike protein.